Catalog No.	PA007363.r2a
Product Name	Anti-mouse CD19 Antibody (Clone: 1D3) | PA007363.r2a
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3
Summary	The anti-mouse CD19 monoclonal antibody (clone: 1D3) was produced in mammalian cells.
Clone	1D3
Isotype	Rat IgG2a Kappa
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: 1D3) specifically binds to the mouse CD19 protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD19 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant rat IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007363.r2a: Recombinant Anti-mouse CD19 Monoclonal Antibody (Clone: 1D3) , Rat IgG2a Kappa, In vivo Grade

The anti-mouse CD19 monoclonal antibody (clone: 1D3) was produced in mammalian cells.

The 1D3 antibody binds to the mouse CD19 protein, a transmembrane protein expressed in all B lineage cells including mouse plasma cells. CD19 plays two major roles in mouse B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References for Anti-mouse CD19 Monoclonal Antibody(clone 1D3):

1、Mitotic History Reveals Distinct Stem Cell Populations and Their Contributions to Hematopoiesis.
Säwén, P., et al. Cell Rep. 2016 Mar 29;14(12):2809-18. doi: 10.1016/j.celrep.2016.02.073. PMID: 26997272
“B cell depletion was conducted according to a previously described protocol (Keren et al., 2011) by intraperitoneally injecting 150 μg/mouse rat anti-mouse CD19 and CD22 (clones 1D3 and CY34.1; Bio X Cell) and rat anti-mouse B220 (clone: RA3-6B2; eBioscience). …Neutrophil depletion was achieved by injecting 500 μg of anti-mouse Ly-6G (clone: RB6-8C5; Bio X Cell) intraperitoneally into mice on days 0 and 5. Analysis was performed on the indicated days after the last injection. …After STA, samples were treated with Exonuclease I (New England Biolabs) at 37°C for 30 min to remove excess primers. …Homeostasis of short-lived blood cells is dependent on rapid proliferation of immature precursors. …Whereas transplantation promoted sustained, long-term proliferation of HSCs, both cytokine-induced mobilization and acute depletion of selected blood cell lineages elicited very limited recruitment of HSCs to the proliferative pool.”

2、Transcription Factor Repertoire of Homeostatic Eosinophilopoiesis.
Bouffi, C., et al. J Immunol. 2015 Sep 15;195(6):2683-95. doi: 10.4049/jimmunol.1500510. PMID: 26268651
“The production of mature eosinophils (Eos) is a tightly orchestrated process with the aim to sustain normal Eos levels in tissues while also maintaining low numbers of these complex and sensitive cells in the blood. …To identify regulators of homeostatic eosinophilopoiesis in mice, we took a global approach to identify genome-wide transcriptome and epigenome changes that occur during homeostasis at critical developmental stages, including Eos-lineage commitment and lineage maturation. …Eos-lineage–committed progenitors (EoPs) were noted to express high levels of granule proteins and contain granules with an ultrastructure distinct from that of mature resting Eos. …Our analyses also delineated a 976-gene Eos-lineage transcriptome that included a repertoire of 56 transcription factors, many of which have never previously been associated with Eos. …In addition, Aiolos and Helios binding sites were significantly enriched in genes expressed by EoPs and Eos with active chromatin, highlighting a potential novel role for Helios and Aiolos in regulating gene expression during Eos development.”

3、Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
Dai, M., et al. Clin Cancer Res. 2015 Mar 1;21(5):1127-38. doi: 10.1158/1078-0432.CCR-14-1339. PMID: 25142145
“The following mAbs were purchased from BioXcell: anti-CD137 (LOB12.3; Cat. #BE0169), anti–PD-1 (RMP1-14; Cat. #BE0146), anti–CTLA-4 (9D9; Cat. #BE0164), anti-CD19 (1D3; Cat. #BE0150), and control (2A3; Cat. #BE0089), and administered as indicated. …To investigate whether there was a functional T-cell response, TLN, or splenocytes were cultured for 16 hours with the Cell stimulation Cocktail (eBioscience), which would induce the activation of cytokines production. …Results were expressed as mean ± SEM. The Student t test was used to compare the statistical difference between two groups and one-way ANOVA was used to compare three or more groups. …Intratumoral injection was more efficacious than intraperitoneal injection in causing rejection also of untreated tumors in the same mice. …Transplanted tumor cells rapidly caused a Th2 response with increased CD19 cells. Successful therapy shifted this response to the Th1 phenotype with decreased CD19 cells and increased numbers of long-term memory CD8 effector cells and T cells making IFNγ and TNFα.”

4、Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia.
Liu, B., et al. J Immunol. 2015 Apr 15;194(8):3583-93. doi: 10.4049/jimmunol.1400951. PMID: 25780046
“Type-2 innate lymphoid cells (ILC2s) and the acquired CD4+ Th2 and Th17 cells contribute to the pathogenesis of experimental asthma; however, their roles in Ag-driven exacerbation of chronic murine allergic airway diseases remain elusive. …In this study, we report that repeated intranasal rechallenges with only OVA Ag were sufficient to trigger airway hyperresponsiveness, prominent eosinophilic inflammation, and significantly increased serum OVA-specific IgG1 and IgE in rested mice that previously developed murine allergic airway diseases. …Furthermore, the acquired CD4+ Th17 cells in Stat6−/−/IL-17–GFP mice, or innate ILC2s in CD4+ T cell–ablated mice, failed to mount an allergic recall response to OVA Ag. After repeated OVA rechallenge or CD4+ T cell ablation, the increase or loss of CD4+ Th2 cells resulted in an enhanced or reduced IL-13 production by lung ILC2s in response to IL-25 and IL-33 stimulation, respectively. …In return, ILC2s enhanced Ag-mediated proliferation of cocultured CD4+ Th2 cells and their cytokine production, and promoted eosinophilic airway inflammation and goblet cell hyperplasia driven by adoptively transferred Ag-specific CD4+ Th2 cells. …Thus, these results suggest that an allergic recall response to recurring Ag exposures preferentially triggers an increase of Ag-specific CD4+ Th2 cells, which facilitates the collaborative interactions between acquired CD4+ Th2 cells and innate ILC2s to drive the exacerbation of a murine allergic airway diseases with an eosinophilic phenotype.”

5、ADAM17 limits the expression of CSF1R on murine hematopoietic progenitors.
Becker, A. M., et al. Exp Hematol. 2015 Jan;43(1):44-52.e1-3. doi: 10.1016/j.exphem.2014.10.001. PMID: 25308957
“Cytokine signaling in hematopoietic progenitors can play an instructive role in directing fate decisions. …We double-sorted 5,000 ADAM17 wild-type or knockout ALPs (CD45.2+) into PBS and then injected into each 800 cG–irradiated B6.SJL (CD45.1+) recipient mice via retro-orbital injection. …As highlighted by this disagreement, the mechanisms by which lymphoid progenitors limit myeloid output in vivo remain incompletely understood. …All-lymphoid progenitors (ALPs) yield few myeloid cells in vivo, but readily generate such cells in vitro. …These data demonstrate that ADAM17 limits CSF1R protein expression on hematopoietic progenitors, but that compensatory mechanisms prevent elevated CSF1R levels from altering lymphoid progenitor potential.”

6、Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.
Carmi, Y., et al. Nature. 2015 May 7;521(7550):99-104. doi: 10.1038/nature14424. PMID: 25924063
“Whereas cancers grow within host tissues and evade host immunity through immune-editing and immunosuppression, tumours are rarely transmissible between individuals. …Much like transplanted allogeneic organs, allogeneic tumours are reliably rejected by host T cells, even when the tumour and host share the same major histocompatibility complex alleles, the most potent determinants of transplant rejection. …Here we find that allogeneic tumour rejection is initiated in mice by naturally occurring tumour-binding IgG antibodies, which enable dendritic cells (DCs) to internalize tumour antigens and subsequently activate tumour-reactive T cells. …Either systemic administration of DCs loaded with allogeneic-IgG-coated tumour cells or intratumoral injection of allogeneic IgG in combination with DC stimuli induced potent T-cell-mediated antitumour immune responses, resulting in tumour eradication in mouse models of melanoma, pancreas, lung and breast cancer. …T cells from these patients responded vigorously to autologous tumour antigens after culture with allogeneic-IgG-loaded DCs, recapitulating our findings in mice.”

7、T cell development requires constraint of the myeloid regulator C/EBP-α by the Notch target and transcriptional repressor Hes1.
Bell, J. J., et al. Nat Immunol. 2013 Dec;14(12):1277-84. doi: 10.1038/ni.2760. PMID: 24185616
“Notch signaling induces gene expression of the T cell lineage and discourages alternative fate outcomes. …Hematopoietic deficiency in the Notch target Hes1 results in severe T cell lineage defects; however, the underlying mechanism is unknown. …We found here that Hes1 constrained myeloid gene-expression programs in T cell progenitor cells, as deletion of the myeloid regulator C/EBP-α restored the development of T cells from Hes1-deficient progenitor cells. …Repression of Cebpa by Hes1 required its DNA-binding and Groucho-recruitment domains. …Our findings establish the importance of constraining developmental programs of the myeloid lineage early in T cell development.”

8、Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.
Dai, M., et al. J Immunother. 2013 May;36(4):248-57. doi: 10.1097/CJI.0b013e3182943549. PMID: 23603859
“Mice with intraperitoneal ID8 ovarian carcinoma or subcutaneous SW1 melanoma were injected with monoclonal antibodies (mAbs) to CD137+PD-1+CTLA4 7–15 days after tumor initiation. …Therapeutic efficacy was associated with a systemic immune response with memory and antigen specificity, required CD4+ cells and involved CD8+ cells and NK cells to a less extent. …This is consistent with shifting the tumor microenvironment from an immunosuppressive Th2 to an immunostimulatory Th1 type and is further supported by PCR data. …Adding an anti-CD19 mAb to the 3 mAb combination in the SW1 model further increased therapeutic efficacy. …Data from ongoing experiments show that intratumoral injection of a combination of mAbs to CD137+PD-1+CTLA4+CD19 can induce complete regression and dramatically prolong survival also in the TC1 carcinoma and B16 melanoma models, suggesting that the approach has general validity.”

9、Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo, Z., et al. J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215. PMID: 24044888
“Therapeutic anti-CD137 (Clone lob12.3; Catalog#BE0169), anti-TIM-3 (Clone RMT3-23; Catalog#BE0115), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036), anti-CD19 (Clone 1D3; Catalog#:BE0150) and control (Clone 2A3; Catalog#:BE0089) were purchased from BioXcell (West Lebanon, NH). …Epithelial ovarian carcinoma (EOC) is the leading cause of death from gynecologic malignancies in the United States and is the fourth most common cause of cancer death in women. …Despite the standard therapy with surgical cytoreduction and the combination of cisplatin and paclitaxel, the treatment efficacy is significantly limited by the frequent development of drug resistance. …Thirdly, although EOC is a devastating disease, metastases are frequently restricted to the peritoneal cavity where the tumor microenvironment is directly accessible, which prevents the need for systemic delivery of immunostimulatory treatments. …The co-stimulatory receptor CD137 is transiently upregulated on T-cells following activation and increases their proliferation and survival when engaged.”

10、Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses.
Purtha, W. E., et al. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):E898-904. doi: 10.1073/pnas.1118155109. PMID: 22431588
“Monoclonal antibodies were purified from the following hybridomas by Bio-X-Cell: TER119 (anti-Ter119), 1D3 (anti-CD19), and A20.1.7 (anti-CD45.2). …The optical density was read at 450 nm, and endpoint dilutions were calculated as three SDs above the background. …IFN regulatory factor-5 (IRF-5) is a transcription factor that has been reported to contribute to the induction of MyD88-dependent IFN responses after viral infection. …Genome-wide studies have identified associations between polymorphisms in the IFN regulatory factor-5 (Irf5) gene and a variety of human autoimmune diseases. …Retroviral expression of DOCK2, but not IRF-5, rescued defects in plasmacytoid dendritic cell and B-cell development, and Irf5−/− mice lacking the mutation in Dock2 exhibited normal plasmacytoid dendritic cell and B-cell development, largely intact type I IFN responses, and relatively normal antibody responses to viral infection.”

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:

Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:

Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:

Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:

Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry

Anti-mouse CD19 Antibody (Clone: 1D3) from: Recombinant Anti-mouse Anti-mouse CD19 Monoclonal Antibody, Rat IgG2a Kappa (Clone: 1D3): PA007363.r2a Syd Labs

No more offers for this product!